Royal Bank of Canada Analysts Give Medidata Solutions (MDSO) a $86.00 Price Target
Medidata Solutions (NASDAQ:MDSO) has been assigned a $86.00 target price by equities researchers at Royal Bank of Canada in a note issued to investors on Friday. The firm currently has a “buy” rating on the stock. Royal Bank of Canada’s target price suggests a potential upside of 21.64% from the company’s current price.
MDSO has been the topic of a number of other research reports. JPMorgan Chase & Co. lowered shares of Medidata Solutions from an “overweight” rating to a “neutral” rating and set a $87.00 target price on the stock. in a report on Tuesday, July 24th. Zacks Investment Research lowered shares of Medidata Solutions from a “hold” rating to a “sell” rating in a report on Tuesday. ValuEngine upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating in a report on Friday, August 24th. Morgan Stanley set a $84.00 target price on shares of Medidata Solutions and gave the stock a “hold” rating in a report on Wednesday, July 25th. Finally, Needham & Company LLC lowered shares of Medidata Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, July 25th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the company’s stock. Medidata Solutions presently has a consensus rating of “Buy” and an average target price of $86.33.
Shares of NASDAQ MDSO traded down $0.12 during trading on Friday, hitting $70.70. 20,218 shares of the company traded hands, compared to its average volume of 766,541. Medidata Solutions has a fifty-two week low of $59.60 and a fifty-two week high of $88.87. The firm has a market capitalization of $4.13 billion, a P/E ratio of 83.52, a P/E/G ratio of 4.35 and a beta of 1.44. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.16.
In other Medidata Solutions news, Director Lee Shapiro sold 12,500 shares of the company’s stock in a transaction dated Thursday, July 26th. The shares were sold at an average price of $76.16, for a total value of $952,000.00. Following the completion of the sale, the director now directly owns 26,028 shares of the company’s stock, valued at approximately $1,982,292.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert Taylor sold 5,000 shares of the company’s stock in a transaction dated Tuesday, July 31st. The stock was sold at an average price of $73.05, for a total transaction of $365,250.00. Following the completion of the sale, the director now directly owns 44,036 shares of the company’s stock, valued at $3,216,829.80. The disclosure for this sale can be found here. Insiders sold a total of 26,788 shares of company stock worth $2,069,857 in the last 90 days. 4.70% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the business. World Asset Management Inc bought a new stake in Medidata Solutions in the 2nd quarter worth about $235,000. Zeke Capital Advisors LLC bought a new stake in Medidata Solutions in the 2nd quarter worth about $239,000. First Republic Investment Management Inc. bought a new stake in Medidata Solutions in the 2nd quarter worth about $242,000. Zions Bancorporation bought a new stake in Medidata Solutions in the 2nd quarter worth about $274,000. Finally, Asset Management One Co. Ltd. grew its position in Medidata Solutions by 102.7% in the 1st quarter. Asset Management One Co. Ltd. now owns 3,948 shares of the company’s stock worth $248,000 after purchasing an additional 2,000 shares in the last quarter.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.
Read More: What Factors Can Affect Return on Equity?
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.